Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19...($- $- $21652211 En...),Health

Endovascular 3,026,181 - - 3,026,181

Total net sales 24,678,392 - - 24,678,392

Royalty income 12,561,950 - - 12,561,950

Total revenues 37,240,342 - - 37,240,342

Operating costs

and expenses:

Cost of

products sold 11,821,673 (154,726) (253,879) 11,413,068

Research and

development 8,891,594 (92,630) (849,678) 7,949,286

Sales and

marketing 7,506,077 (71,474) (262,148) 7,172,455

General and

administrative 5,999,887 (4,898) (1,627,173) 4,367,816

Total

operating

costs and

expenses 34,219,231 (323,728) (2,992,878) 30,902,625

Income from

operations 3,021,111 323,728 2,992,878 6,337,717

Interest and other

income, net 422,262 - - 422,262

Pre-tax income 3,443,373 323,728 2,992,878 6,759,979

Income tax expense 1,057,548 110,068 1,017,579 2,185,194

Net income $2,385,825 $213,660 $1,975,299 $4,574,785

Basic earnings per

share $0.20 $0.02 $0.16 $0.38

Diluted earnings per

share $0.19 $0.02 $0.16 $0.36

Weighted average

common shares

outstanding 12,037,997 12,037,997 12,037,997 12,037,997

Diluted weighted

average common

shares

outstanding 12,633,529 12,633,529 12,633,529 12,633,529

Note: To supplement our consolidated financial statements presented in accordance with GAAP, Kensey Nash Corporation uses non-GAAP measures of as adjusted net income and earnings per shar
'/>"/>